Wegovy DE — Understanding Semaglutide for Weight Management

What the trial data says about Wegovy's effect on weight

The STEP 1 trial, whose results appear in the New England Journal of Medicine, remains the cornerstone of how clinicians understand semaglutide 2.4mg. Over 68 weeks, adults living with obesity who used Wegovy alongside lifestyle changes lost an average of roughly 15% of their starting body weight. That is a meaningful clinical result: at that scale, many people also saw improvements in blood pressure, cholesterol and blood-sugar markers. The comparison group, following lifestyle guidance alone, lost about 2.4% on average.

Since that trial, the approval picture has moved. The MHRA approved a 7.2mg maintenance dose in January 2026 and then, on 14 April 2026, a dedicated single-dose 7.2mg pen designed for once-weekly use. Early data for that higher dose reported average weight loss of around 20.7% over 72 weeks, bringing it closer to tirzepatide outcomes. Whether 7.2mg is appropriate for any individual is a clinical decision, not one made by the dose number alone. You can read more about what each stage of treatment involves on the Wegovy overview page.

It is also worth knowing that semaglutide received MHRA conditional approval in July 2026 for a form of liver disease called MASH in adults with moderate-to-advanced fibrosis, a separate indication that has no bearing on weight-management prescribing, but which illustrates the growing body of evidence behind this molecule.

How Wegovy's approved dose schedule works in practice

Treatment begins at a low 0.25mg weekly dose. That starting point exists because semaglutide's most common side effects (nausea, loose stools, indigestion) are most pronounced in the early weeks; a gradual beginning gives the body time to adjust. From there, the dose steps up roughly every four weeks, through 0.5mg, 1mg and 1.7mg, to the 2.4mg maintenance level. The prescriber guides that progression; it is not automatic, and some people stay longer at a particular stage if tolerated better there.

For people who need more, the 7.2mg pathway is now available, though supply and individual suitability are confirmed at consultation. If you'd like to understand how each stage differs, the Wegovy dose guide goes through the schedule in detail. One thing worth noting for anyone switching from a clinic abroad: if you've already been titrated onto a dose, a UK prescriber will want to see evidence of your current treatment before continuing at that level, that's standard clinical practice, not an obstacle.

Storage is straightforward for most people: keep the pen refrigerated between 2°C and 8°C. The Patient Information Leaflet sets out the exact room-temperature window allowed, and that is always the definitive reference. The pen itself, when it arrives, comes in plain unbranded packaging via DPD tracked delivery, so there's nothing to indicate what's inside if that matters to you.

Who can be prescribed Wegovy in the UK, and the NHS versus private routes

The licensed eligibility criteria are: adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, raised cholesterol or obstructive sleep apnoea. Lower thresholds apply for some ethnic backgrounds under UK guidance. BMI alone is never the full picture, the prescriber also considers your medical history, any medicines you take, and whether there are contraindications.

On the NHS, NICE's appraisal of semaglutide (TA875) recommends it only within specialist weight management services and for a maximum of two years, with strict comorbidity requirements. Waiting lists for those services are long in most parts of England, and criteria in Scotland, Wales and Northern Ireland differ. Privately, the process is faster: a registered prescriber assesses your information, and if you're suitable, treatment can move quickly without waiting for a referral pathway. The weight management treatment overview explains both routes side by side.

Wegovy is not suitable during pregnancy, while breastfeeding, or for anyone trying to conceive. It is not licensed for under-18s. Anyone with a history of medullary thyroid carcinoma or MEN2 should discuss their history with a prescriber before any GLP-1 medicine is considered.

Side effects to know about before you start

Gastrointestinal effects are the most commonly reported: nausea tends to be most noticeable in the first few weeks or after a dose increase, and usually settles as the body adjusts. Other effects people report include constipation, diarrhoea, indigestion, headache and fatigue. Most are mild to moderate and temporary, though they affect people differently.

One effect that warrants prompt medical attention is severe, persistent stomach pain, particularly pain that spreads to the back, with or without vomiting. The MHRA Drug Safety Update programme highlighted acute pancreatitis as a known, infrequent but serious risk associated with GLP-1 medicines, and issued specific updated guidance on this in January 2026. If that symptom pattern develops, the right step is to contact a healthcare professional promptly rather than waiting to see whether it passes. Side effects can also be reported directly via the Yellow Card scheme, which is how the MHRA monitors medicines in real-world use.

Anyone using oral contraceptives should be aware that semaglutide's effect on gastric emptying can, in theory, affect absorption, your prescriber can advise on whether any adjustment to contraception is appropriate for you specifically. A conversation with our clinical team before starting is the right place to raise that kind of question.

If you're ready to find out whether Wegovy is clinically suitable for you, starting a free consultation is the first step, a GPhC-registered prescriber reads every submission personally, the same day.